Table 3 Adverse Events by Treatment Groupa

From: Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson’s disease: a randomized phase 2 trial

 

No. (%) of patientsb

dFMT (n = 36)

aFMT (n = 36)

Any adverse event

Any serious adverse eventc

0 (0)

0 (0)

Discontinuation due to adverse event

Adverse events occurring in patients

 Abdominal pain

1 (2.8%)

1 (2.8%)

 Abdominal bloating

1 (2.8%)

0 (0)

 Diarrhea

1 (2.8%)

1 (2.8%)

 Nausea

0 (0)

1 (2.8%)

 Vomiting

0 (0)

0 (0)

 Infection

0 (0)

0 (0)

 Fever

0 (0)

0 (0)

 Pneumonia

0 (0)

0 (0)

 Bacteraemia

0 (0)

0 (0)

 Respiratory difficulties

0 (0)

0 (0)

 Proctalgia

0 (0)

0 (0)

 Fatigue

0 (0)

0 (0)

 Weight loss

0 (0)

0 (0)

  1. dFMT donor fecal microbiota transplantation, aFMT autologous fecal microbiota transplantation
  2. aAdverse events were categorized using the Common Terminology Criteria for Adverse Events
  3. bValues are presented as numbers (percentages) of participants experiencing the event at least once
  4. cDefined as any adverse event that occurred at any dose and resulted in death, a life-threatening adverse event, inpatient hospitalization or prolongation of an existing hospitalization, persistent or significant disability
Back to article page